After previous studies on NRs like ERα and TR-β, we are hopeful that the discovery of the tissue-specific transcriptional function of FXR will allow us to examine the targeted therapeutic approaches for NASH and other liver diseases. This evidence concerns the gene ESR1 and metabolic dysfunction-associated steatohepatitis.